Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Circulating free testosterone is an independent predictor of advanced disease in patients with clinically localized prostate cancer.

Schnoeller T, Jentzmik F, Rinnab L, Cronauer MV, Damjanoski I, Zengerling F, Ghazal AA, Schrader M, Schrader AJ.

World J Urol. 2013 Apr;31(2):253-9. doi: 10.1007/s00345-012-0902-5. Epub 2012 Jul 5.

PMID:
22763628
[PubMed - indexed for MEDLINE]
2.

Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2011 Apr;107(8):1243-9. doi: 10.1111/j.1464-410X.2010.09582.x. Epub 2010 Sep 30.

PMID:
20883480
[PubMed - indexed for MEDLINE]
3.

Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.

Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A, Zanni G, Ferrari M, Castiglione F, Clementi MC, Rigatti P, Montorsi F.

World J Urol. 2013 Apr;31(2):275-80. doi: 10.1007/s00345-012-0856-7. Epub 2012 Mar 24.

PMID:
22441310
[PubMed - indexed for MEDLINE]
4.

Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Salonia A, Gallina A, Abdollah F, Briganti A, Capitanio U, Suardi N, Ferrari M, Raber M, Colombo R, Freschi M, Rigatti P, Montorsi F.

World J Urol. 2012 Aug;30(4):533-9. doi: 10.1007/s00345-011-0761-5. Epub 2011 Sep 21.

PMID:
21935733
[PubMed - indexed for MEDLINE]
5.

Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy.

Salonia A, Gallina A, Briganti A, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F.

Cancer. 2011 Nov 15;117(22):5029-38. doi: 10.1002/cncr.26136. Epub 2011 Apr 14.

PMID:
21495024
[PubMed - indexed for MEDLINE]
Free Article
6.

Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.

Porcaro AB, Ghimenton C, Petrozziello A, Sava T, Migliorini F, Romano M, Caruso B, Cocco C, Antoniolli SZ, Lacola V, Rubilotta E, Monaco C.

Anticancer Res. 2012 Oct;32(10):4523-32.

PMID:
23060581
[PubMed - indexed for MEDLINE]
7.

Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy.

Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F.

Clin Cancer Res. 2012 Jul 1;18(13):3648-57. doi: 10.1158/1078-0432.CCR-11-2799. Epub 2012 May 15.

PMID:
22589393
[PubMed - indexed for MEDLINE]
Free Article
8.

Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer.

Cabral PH, Iwamoto MW, Fanni VS, Barros Lda R, Cardoso SN, Mello LF, Glina S.

Int Braz J Urol. 2013 Mar-Apr;39(2):173-81. doi: 10.1590/S1677-5538.IBJU.2013.02.04.

PMID:
23683664
[PubMed - indexed for MEDLINE]
Free Article
9.

Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis of prostate cancer and subsequent cluster selection of the patient population undergoing standard radical prostatectomy.

Porcaro AB, Migliorini F, Petrozziello A, Sava T, Romano M, Caruso B, Cocco C, Ghimenton C, Zecchinini Antoniolli S, Lacola V, Rubilotta E, Monaco C, Comunale L.

Urol Int. 2013;90(1):45-55. doi: 10.1159/000343430. Epub 2012 Nov 2.

PMID:
23128438
[PubMed - indexed for MEDLINE]
10.

Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.

Douglas TH, Morgan TO, McLeod DG, Moul JW, Murphy GP, Barren R 3rd, Sesterhenn IA, Mostofi FK.

Cancer. 1997 Jul 1;80(1):107-14.

PMID:
9210715
[PubMed - indexed for MEDLINE]
11.

Preoperative serum sex hormone-binding globulin as a predictive marker for extraprostatic extension of tumor in patients with clinically localized prostate cancer.

Lee SE, Chung JS, Han BK, Park CS, Moon KH, Byun SS, Choe G, Hong SK.

Eur Urol. 2008 Dec;54(6):1324-32. doi: 10.1016/j.eururo.2008.02.032. Epub 2008 Mar 7.

PMID:
18339472
[PubMed - indexed for MEDLINE]
12.

Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.

Gustafsson O, Norming U, Gustafsson S, Eneroth P, Aström G, Nyman CR.

Br J Urol. 1996 Mar;77(3):433-40.

PMID:
8814852
[PubMed - indexed for MEDLINE]
13.

The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration.

Monda JM, Myers RP, Bostwick DG, Oesterling JE.

Urology. 1995 Jul;46(1):62-4.

PMID:
7541588
[PubMed - indexed for MEDLINE]
14.

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy.

Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T.

J Urol. 2003 May;169(5):1670-5.

PMID:
12686805
[PubMed - indexed for MEDLINE]
15.

The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.

Corcoran NM, Casey RG, Hong MK, Pedersen J, Connolly S, Peters J, Harewood L, Gleave ME, Costello AJ, Hovens CM, Goldenberg SL.

BJU Int. 2012 Jul;110(1):36-42. doi: 10.1111/j.1464-410X.2011.10681.x. Epub 2011 Nov 15.

PMID:
22085203
[PubMed - indexed for MEDLINE]
16.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
[PubMed - indexed for MEDLINE]
17.

Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.

Horiguchi A, Nakashima J, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, Marumo K, Murai M.

Prostate. 2003 Jun 15;56(1):23-9.

PMID:
12746843
[PubMed - indexed for MEDLINE]
18.

Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.

Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC.

J Urol. 1998 Dec;160(6 Pt 1):2089-95.

PMID:
9817330
[PubMed - indexed for MEDLINE]
19.

Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.

García-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, Franco A, Alvarez-Vijande R, Ribal MJ, Alcaraz A.

BJU Int. 2012 Dec;110(11 Pt B):E541-6. doi: 10.1111/j.1464-410X.2012.11232.x. Epub 2012 May 15.

PMID:
22584031
[PubMed - indexed for MEDLINE]
20.

Preoperative hormonal pattern in patients undergoing radical prostatectomy due to prostate cancer.

García-Cruz E, Castañeda-Argáiz R, Carrión A, Alcover J, Sallent A, Leibar-Tamayo A, Romero-Otero J, Alcaraz A; Red Española de Investigación en Salud del Hombre (REISHO).

Actas Urol Esp. 2013 May;37(5):280-5. doi: 10.1016/j.acuro.2012.08.002. Epub 2012 Dec 13. English, Spanish.

PMID:
23246101
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk